Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zhaoke Ophthalmology's Enterprise Value is €64.06 Mil.
Zhaoke Ophthalmology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-24.18 Mil. Therefore, Zhaoke Ophthalmology's EV-to-EBIT ratio for today is -2.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Zhaoke Ophthalmology's Enterprise Value is €64.06 Mil.
Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-24.18 Mil. Therefore, Zhaoke Ophthalmology's EV-to-EBITDA ratio for today is -2.65.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Zhaoke Ophthalmology (FRA:9FX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-24.18 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-24.18 Mil.
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €3.87 Mil.
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-31.47 Mil.
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-32.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology Enterprise Value Related Terms
Zhaoke Ophthalmology Enterprise Value Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9FX vs VRTX, REGN, MRNA: Enterprise Value Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Zhaoke Ophthalmology's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (FRA:9FX) has a Enterprise Value of €64.06 Mil as of Sep. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhaoke Ophthalmology and its competitors.
Is Zhaoke Ophthalmology's Enterprise Value too high?
Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Enterprise Value compare to VRTX and REGN?
Zhaoke Ophthalmology's Enterprise Value of €64.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhaoke Ophthalmology and its competitors. Zhaoke Ophthalmology's current Enterprise Value is €64.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current Enterprise Value of €64.06 Mil. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current Enterprise Value is €64.06 Mil. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current Enterprise Value is €64.06 Mil as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.
Key valuation signals for FRA:9FX:
Enterprise Value: €64.06 Mil
GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for FRA:9FX
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9FX has been successfully added to your 
